Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Alec Machiels

Co-Founder and Board Member

1 past transactions

Potentia Pharmaceuticals

Acquisition in 2014
Potentia Pharmaceuticals is a biotechnology company, develops anti-inflammatory drugs/therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.